Hjem › Blærekreft › Ohio › Cincinnati
Kliniske studier for Blærekreft i Cincinnati, OH
10 studier for Blærekreft søker deltakere på steder i og rundt Cincinnati (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Oncology Hematology Care Inc-Kenwood, Cincinnati
- Bethesda North Hospital, Cincinnati
- og 3 flere
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
RekruttererFase 2
- TriState Urologic Services PSC Inc. dba The Urology Group ( Site 0122), Cincinnati
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
RekruttererFase 2
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi unna
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
RekruttererFase 3
- Oncology Hematology Care Clinical Trials, LLC, Fairfield · 15 mi unna
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
RekruttererFase 3
- TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0822), Cincinnati
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RekruttererFase 3
- University of Cincinnati Medical Center, Cincinnati
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
RekruttererFase 2
- The Urology Group (Solaris), Cincinnati
- University of Cincinnati Cancer Center, Cincinnati
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RekruttererFase 1
- University of Cincinnati Medical Center (UCMC), Cincinnati
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
RekruttererFase 1/2
- University of Cincinnati Medical Center, Cincinnati
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Cincinnati
Blærekreft-studier i andre byer
- New York City, NY35 studier
- Nashville, TN31 studier
- Houston, TX31 studier
- Dallas, TX27 studier
- Boston, MA26 studier
- Washington, DC26 studier
- Los Angeles, CA24 studier
- Baltimore, MD24 studier
- St. Louis, MO22 studier
- Philadelphia, PA21 studier
- Seattle, WA21 studier
- Edison, NJ21 studier
Andre studier i Cincinnati
- Ikke-småcellet lungekreft35 studier
- Kreft (alle typer)27 studier
- Brystkreft25 studier
- Hjertesvikt24 studier
- Kolorektal kreft21 studier
- Akut myelogen leukemi20 studier
- Metastatisk kreft20 studier
- Eggstokkreft19 studier
- Lungekreft19 studier
- Fedme19 studier
- Prostatakreft18 studier
- Multipelt myelom17 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.